

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/17551 A2

- (51) International Patent Classification⁷: A61K 39/00 (74) Agent: PRIVETT, Kathryn, Louise; SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (21) International Application Number: PCT/EP00/08784
- (22) International Filing Date:
7 September 2000 (07.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
9921146.8 07 September 1999 (07.09.1999) GB
07 Mar 02 30 m3
- (71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM BIOLOGICALS S.A.
[BE/BE]; rue de l'Institut, 89, B-1330 Rixensart (BE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): WETTENDORFF, Martine, Anne, Cecile [BE/BE]; SmithKline Beecham Biologicals s.a., Rue de l'Institut 89, B-1330 Rixensart (BE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOSITION

(57) Abstract: Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.

WO 01/17551 A2